---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-003070"
form_type: "8-K"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2025-02-07T23:59:59+00:00"
generated_at: "2026-05-27T00:57:06.816405+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Eton awarded patent for ET-600 desmopressin oral solution expiring 2044; NDA filing expected Q2 2025

## Summary
- USPTO granted U.S. Patent No. 12,214,010 covering ET-600's proprietary desmopressin oral solution formulation.
- Patent expires in 2044 and is expected to be listed in FDA Orange Book upon product approval.
- ET-600 treats diabetes insipidus; no FDA-approved oral liquid currently available for pediatric patients.
- Pivotal bioequivalence study ongoing; results expected at end of February 2025.
- If positive, NDA filing with FDA anticipated by Q2 2025.

## SEC filing metadata
- accession: 0001437749-25-003070
- form_type: 8-K
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2025-02-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000143774925003070/0001437749-25-003070-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000143774925003070/eton20250203_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-003070
- JSON: https://secwatch.observer/filing/0001437749-25-003070.json
- Plain text: https://secwatch.observer/filing/0001437749-25-003070.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.